Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence-Reference-Cited by-同舟云学术

Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence

Published:2021-05-11 Issue:10 Volume:56 Page:2355-2366
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Murata Makoto^ORCID,Terakura Seitaro^ORCID,Wake Atsushi,Miyao Kotaro^ORCID,Ikegame Kazuhiro^ORCID,Uchida Naoyuki^ORCID,Kataoka Keisuke^ORCID,Miyamoto Toshihiro^ORCID,Onizuka Makoto,Eto Tetsuya,Doki Noriko,Ota Shuichi^ORCID,Sato Maho,Hashii Yoshiko,Ichinohe Tatsuo^ORCID,Fukuda Takahiro,Atsuta Yoshiko^ORCID,Okamoto Shinichiro,Teshima Takanori^ORCID

Funder

Japan Agency for Medical Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-021-01304-y.pdf

Reference46 articles.

1. Zeiser R, Blazar BR. Acute graft-versus-host disease—biologic process, prevention, and therapy. N. Engl J Med. 2017;377:2167–79.

2. MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transpl. 2015;21:761–7.

3. Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, et al. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2013;19:1183–9.